Menu
ncarol.com
  • Home
  • Education
  • Health
  • Books
  • Technology
  • Financial
  • Entertainment
  • Real Estate
  • Music
ncarol.com

Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
ncarol.com/10175183

Trending...
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
DURHAM, N.C., May 27, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pemetrexed Lyo. Injection to its line of chemotherapy drugs. The new drug is formulated as a sterile lyophilized (freeze-dried) powder to be reconstituted for intravenous infusion. Pemetrexed Lyo. Injection is therapeutically equivalent to Eli Lilly and Company's ALIMTA® and approved to treat Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Malignant Pleural Mesothelioma (MPM), a cancer of the inside lining of the chest cavity.1 Accord's product is offered in vials of 100mg, 500mg, and 1000mg strengths and is currently available to ship.

Pemetrexed Lyo. Injection is FDA-approved for use as a first-line treatment for locally advanced or metastatic NSCLC with non-squamous tissue type, a maintenance drug for metastatic NSCLC, a treatment for NSCLC that recurs after prior chemotherapy, and a treatment for MPM in patients whose cancer can't be removed surgically.2

"Accord Healthcare US has distinguished itself in oncology injectables, and the introduction of Pemetrexed Lyo. Injection to our portfolio strengthens our offering of oncology medications," said Accord CEO Jeff Hampton. "We are committed to making more generics available to patients. Our technical capabilities and manufacturing infrastructure have defined our company's history and the patients shape our future."

More on ncarol.com
  • New research identifies The Discovery Gap: Seven in 10 Americans say travel is no longer just about getting away
  • PropAccount.com Adds Equities to Its Multi-Asset Prop Firm Platform, Opening the Door to the World's Largest Trading Market
  • Ailias Launches Global Partner Programme for AI-Powered Conversational Digital Humans in Events and Experiences
  • Village People Headline "Rock The Rainbow" Phuket Pride Finale 2026
  • SilverBow Strategies Launches RFPArchon™, the First Product in Its Artemis AI Solutions™ Suite

Important Safety Information: Pemetrexed Lyo. Injection may cause fatigue or nausea and vomiting. Other possible side effects are serious, including fast heartbeat, chest pain, blistering and other skin reactions, and difficulty breathing. Pemetrexed is in a class of medications called antifolate antineoplastic agents and works by blocking the action of a certain substance in the body that may help cancer cells multiply.2

Further information about safety and potential side effects can be found in our product insert.

Pemetrexed was approved by the FDA for the treatment of Malignant Pleural Mesothelioma.3 For more information, please visit the Products page at Accord Healthcare US.

About Accord Healthcare US

Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company. Accord is committed to improving lives by increasing access to medicines while also providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines. Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do. Accord is headquartered in Durham, North Carolina. The Intas network markets its products in 80 countries. To learn more, visit the Accord website.

More on ncarol.com
  • New from Regal House Publishing, The Unfinished Business, its tricky inheriting a ghost-busting firm
  • Sawasdee Anime Launches Animenture: A Gamified SNS Connecting Global Fans to 2,000+ Anime Sites
  • "LOOK UP CAFE TOKYO SKYTREE" to Open on May 22, 2026 on the 5th floor of TOKYO SKYTREE®. This Date also Marks TOKYO SKYTREE's 14th Anniversary
  • "Rehabilitative Prison Program Compromised by Alleged Staff Misconduct, Whistleblower Claims"
  • Creator Space LA brings together industry leaders for an immersive AI showcase, demonstrations, and film hackathon

References

1 Access data FDA.gov. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021462s021lbl.pdf. Accessed May 2022.

2 Pemetrexed Injection, National Library of Medicine, MedlinePlus. Available at: https://medlineplus.gov/druginfo/meds/a607043.html. Accessed May 2022.

3 FDA drug approval summaries: pemetrexed (Alimta), U.S. Food and Drug Administration. Available at: https://pubmed.ncbi.nlm.nih.gov/15477632/. Accessed May 2022.

Media Contact:
Kellyann Zuzulo
Em-Press Media
[email protected]
215.287.7291

SOURCE Accord Healthcare, Inc.
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Hazel E Hosts Starline Tours Bus to Sonic Desert - A Launch to Coachella
  • Contracting Resources Group and Aalis Management Consulting Launch ARG Joint Venture Under SBA Mentor-Protégé Program
  • Now Presenting Flights of Fancy
  • Card makers turn to Pink and Main for tools to support their craft
  • Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
  • EduCare Inc. Bridges Critical Gap in Breast Cancer Education with Spanish COPE Library Launch
  • Engineering leaders from industry, academia to gather at IISE Annual Conference & Expo in Arlington, Texas
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • BestDoc Launches AI Call Center for Healthcare
  • Acuvance Appoints Sandeep Sabharwal to Board of Directors, Strengthening Leadership to Support Continued Platform Growth
  • Grange Insurance Association to Rebrand as Granwest Insurance on July 1, 2026
  • Dr. Rosendo Icochea, MD Recognized for Contributions to Surgical Education and Medical Research
  • Giftella Launches AI Gift-Finder App That Replaces Guesswork With Personalized Picks in Seconds
  • Beverly.io Announces Nationwide Expansion and Poppins Payroll Partnership for Families
  • New Book: The Battle for Truth and Shadows - Guardians of Light - Epic Fantasy Unveils a War Between Light and Deception
  • Comfortable Clothing for Every Moment
  • Clash of Prompts: The World's First AI Prompt Battle Royale
  • $7.6 Billion US Crypto ATM Market by 2034; California and Texas Crypto ATM Deployments for Bitcoin Bancorp (Stock Symbol: BCBC); 1000 Kiosk Inventory
  • MainConcept Announces Multiview Encoding for Apple Immersive Video
  • CCHR Rejects Global Psychiatric Push to Electroshock Children
_catLbl0 _catLbl1

Popular on ncarol.com

  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals - 361
  • Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets - 147
  • Larry R. Wasion Highlights Jump Gate I: Time Chair. The Opening Novel in His Expansive Science Fiction Series
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
  • Sycor Introduces Spring Release 2026 of Sycor.Rental with AI-Driven Innovations and Enhanced Service Processes
  • Rhealize Strategic Talent Advisory Co-Founder Dona Baker to Speak at DisruptHR YEG 15.0 in Edmonton on Hiring Innovation
  • UK Financial Ltd Tokenized LTNS 1, A $1.1 T Asset-Backed ERC-3643 Security Token with 11 On-Chain Contracts Verifying, Compliant Real-World Value
  • Pacific Emblem Company Launches "Happy 250th Birthday America" Collection and Proud Supporter of the Gary Sinise Foundation
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)

Similar on ncarol.com

  • Studica Robotics Receives 2026 Partner Excellence Award from FIRST® Robotics Canada
  • PropAccount.com Adds Equities to Its Multi-Asset Prop Firm Platform, Opening the Door to the World's Largest Trading Market
  • Creator Space LA brings together industry leaders for an immersive AI showcase, demonstrations, and film hackathon
  • Uxur Taxi Unveils Luxury 3,000‑Mile Private Driver Service for Nationwide Travel
  • UK Financial Ltd Launches UKFL Premier One as Its Official Broadcast Channel for Premium Content, Podcasts & Independent Expert Analysis
  • Dual-Engine Growth Strategy Unleashed Targeting a $9.1B Market and the Exploding AI Biotech Revolution: KALA BIO (N A S D A Q: KALA)
  • Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
  • AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)
  • BestDoc Launches AI Call Center for Healthcare
  • Acuvance Appoints Sandeep Sabharwal to Board of Directors, Strengthening Leadership to Support Continued Platform Growth
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute